Clinical Trial Detail

NCT ID NCT03726879
Title A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Cyclophosphamide + Doxorubicin

Atezolizumab + Cyclophosphamide + Doxorubicin

Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab

Atezolizumab + Pertuzumab + Trastuzumab

Pertuzumab + Trastuzumab

Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult senior

No variant requirements are available.